Increased Expression of Membrane Type 3-matrix Metalloproteinase in Human Atherosclerotic Plaque: Role of Activated Macrophages and Inflammatory Cytokines
Overview
Authors
Affiliations
Background: Matrix metalloproteinases (MMPs) are thought to play a prominent role in atherogenesis and destabilization of plaque. Pericellularly localized membrane-type (MT)-MMPs activate secreted MMPs. We investigated the hypothesis that MT3-MMP is expressed in human atherosclerotic plaques and is regulated by locally produced inflammatory cytokines and oxidized low-density lipoprotein (Ox-LDL).
Methods And Results: Expression and cellular localization of MT3-MMP in normal and atherosclerotic human coronary arteries were examined using specific antibodies. Abundant MT3-MMP expression was noted in medial smooth muscle cells (SMCs) of normal arteries. In atherosclerotic arteries, MT3-MMP expression was observed within complex plaques and colocalized with SMCs and macrophages (Mphi). Cultured human monocyte-derived Mphi constitutively expressed MT3-MMP mRNA and proteolytically active protein, as demonstrated by mRNA analyses, immunoblotting, and gelatin zymography, respectively. Ox-LDL, tumor necrosis factor-alpha, or macrophage colony-stimulating factor caused dose- and time-dependent increases in steady-state levels of MT3-MMP mRNA in cultured Mphi. This correlated with a 2- to 4-fold increase in levels of MT3-MMP immunoreactive protein and enzymatic activity in Mphi membranes. Confocal microscopy and flow cytometry confirmed induction and spatial distribution of MT3-MMP protein from intracellular domains to the Mphi plasma membrane by Ox-LDL, tumor necrosis factor-alpha, or macrophage colony-stimulating factor.
Conclusions: MT3-MMP is expressed by SMCs and Mphi in human atherosclerotic plaques. Proinflammatory molecules cause a progressive increase in the expression of MT3-MMP in cultured Mphi. Our results suggest a mechanism by which inflammatory molecules could promote Mphi-mediated degradation of extracellular matrix and thereby contribute to plaque destabilization.
Salica A, Cammisotto V, Scaffa R, Folino G, De Paulis R, Carnevale R Antioxidants (Basel). 2024; 13(10).
PMID: 39456434 PMC: 11505158. DOI: 10.3390/antiox13101180.
Extracellular Matrix Remodeling Biomarkers in Coronary Artery Disease.
Theofilis P, Sagris M, Oikonomou E, Antonopoulos A, Lazaros G, Theofilis A Curr Top Med Chem. 2022; 22(28):2355-2367.
PMID: 36284400 DOI: 10.2174/1568026623666221024091758.
Dziedzic E, Gasior J, Tuzimek A, Dabrowski M, Jankowski P Biology (Basel). 2022; 11(7).
PMID: 36101382 PMC: 9311593. DOI: 10.3390/biology11071001.
Association of Matrix Metalloproteinases with Coronary Artery Calcification in Patients with CHD.
Polonskaya Y, Kashtanova E, Murashov I, Striukova E, Kurguzov A, Stakhneva E J Pers Med. 2021; 11(6).
PMID: 34205079 PMC: 8228219. DOI: 10.3390/jpm11060506.
Xue Y, Chen H, Zhang S, Bao L, Chen B, Gong H Oxid Med Cell Longev. 2021; 2021:8819231.
PMID: 33728029 PMC: 7935581. DOI: 10.1155/2021/8819231.